| | |

Mesothelioma and Metastatic Cancer: New Test Can Reliably Tell the Difference

ByAlex Strauss
mesothelioma and metastatic cancer

Italian scientists have come up with what they believe is a nearly foolproof way to tell the difference between mesothelioma and metastatic cancer. 

Malignant mesothelioma is a membrane cancer caused by asbestos exposure. Metastatic cancer can start anywhere in the body. It can cause tumors on the pleural membrane that may be mistaken for mesothelioma. 

It is important for doctors to distinguish between these two types of malignancies. Mesothelioma and metastatic cancer are often treated differently. The Italian researchers say two biomarkers may make it easier to know which is which. 

The Difference Between Mesothelioma and Metastatic Cancer

Metastatic cancer or metastatic carcinoma is cancer that has spread to another part of the body from where it started. This usually happens via the lymphatic system. Once cancer cells are in the lymph nodes, they can travel elsewhere in the body and seed new tumors. 

Pleural mesothelioma starts on a membrane called the pleura. Mesothelioma and metastatic cancer on the pleura look very similar. But the drugs doctors use to combat metastatic breast or colon cancer tumors on the pleura are different from the ones used to fight pleural mesothelioma.

Correctly identifying the cancer type and choosing the right drug is especially critical with mesothelioma. It is one of the fastest growing cancers and is almost always fatal. 

Two Key Biomarkers: CRLA-4 and BAP1

All tumors, including mesothelioma and metastatic cancer, contain clues to their origins. These are usually proteins. Scientists call these signposts “biomarkers”. Biomarkers may appear in the blood or other body fluids or in tissue. 

In the new report, Italian researchers focused on a 2-part panel that tests for the proteins Claudin-4 and BAP1. They used samples of lung fluid and tumor tissue from three groups of people: 49 cases of pleural mesothelioma, 49 people with benign growths on the pleura, and 49 people with cancer than had spread to the pleura. 

The differences between mesothelioma and metastatic cancer were clear.

“Claudin-4 strongly stained all metastatic carcinomas and tested completely negative in normal mesothelium, benign reactive mesothelial hyperplasia, and malignant mesothelioma,” reports lead study author Livia Bernardi. 

All but one of the metastatic cancer samples tested positive for BAP1, too. But BAP1 was low or missing in 88 percent of the mesothelioma cell samples. 

Together, the two-part “Brescia panel” offers a simple but powerful way to distinguish between mesothelioma and metastatic cancer. 

“Double negativity was evident in all malignant mesotheliomas, and double positivity was observed in all metastatic carcinomas,” the researchers write. “This 2-hit panel is probably the best compromise for differentiating malignant mesothelioma and metastatic carcinoma on either cytology [fluid sample] or biopsy specimens.”

A thorough work history is another major part of mesothelioma diagnosis. Almost all mesothelioma patients can trace their disease to asbestos exposure. 

Source:

Bernardi, L, et al, “The ‘Brescia panel’ (Claudin-4 and BRCA-associated protein 1) in the differential diagnosis of mesotheliomas with epithelioid features versus metastatic carcinomas”, October 12, 2020, Cancer Cytopathology, Epub ahead of print, https://acsjournals.onlinelibrary.wiley.com/doi/10.1002/cncy.22368

Similar Posts

  • |

    Mesothelioma Blood Test May Be Possible

    ByAlex Strauss

    An international team of researchers is studying the proteins found on the surface of cancer cells in an effort to improve mesothelioma diagnosis. The team, made up of scientists from the US, Switzerland, Italy and Chile, has just published their findings on a new kind of test to identify protein-derived mesothelioma biomarkers in blood serum. Mesothelioma is an aggressive cancer of the membranes around organs. Because the most common mesothelioma biomarker, mesothelin, is also overproduced by other kinds of cancer cells, it has only limited diagnostic value. A test to identify a set of proteins produced specifically by mesothelioma cells could greatly improve diagnostic accuracy. Led by Ferdinando Cerciello and Bernd Wollscheid of the Institute of Molecular Systems Biology in…

  • | |

    Needle Biopsy “Simple, Safe & Accurate” for Mesothelioma

    ByAlex Strauss

    Mesothelioma researchers in China say a biopsy method that involves a single skin puncture can produce good diagnostic results for mesothelioma patients with little pain or risk. The study focused on percutaneous (through the skin) biopsy in patients who had unexplained fluid buildup or swelling in their abdomens. Abdominal distension and fluid buildup (called ascites) can be signs of peritoneal mesothelioma, a rare but aggressive cancer of the abdominal lining caused by exposure to asbestos. Peritoneal mesothelioma accounts for less than 30% of all mesothelioma cases. Because the symptoms may be vague and often develop many decades after asbestos exposure, peritoneal mesothelioma can be especially challenging to diagnose.  Misdiagnosis and under-diagnosis are not uncommon. In the newest study on percutaneous…

  • | |

    Inflammation Both “Friend and Foe” in Mesothelioma

    ByAlex Strauss

    An immune system response that causes mesothelioma symptoms such as fever, fatigue, and weight loss may also be helpful to clinicians as a way to find and treat the disease. Scientists with The Asbestos Diseases Research Institute in Sydney, Australia make that case that both systemic inflammation (throughout the body) and at the site of a tumor – has long been associated with mesothelioma and other cancers. Inflammation results when the body attempts to address the imbalances of cancer by producing more of certain immune system cells. Some inflammatory markers, such as CD+8 T-cells and C-reactive protein, have been linked to better prognosis in mesothelioma. Other inflammatory markers, such as certain macrophages and a high neutrophil-to-lymphocyte ratio, can signal the…

  • | |

    FDG PET-CT Results Could Lead to Improved Mesothelioma Treatment

    ByAlex Strauss

    In a recent study, researchers say a better understanding of certain diagnostic criteria could result in more targeted treatments for malignant mesothelioma. In a recent published report, doctors from the medical school at Dicle University in Diyarbakir, Turkey measured the relationship between PET-CT scan results and survival in 177 patients with malignant pleural mesothelioma. The patients were diagnosed between April 2007 and April 2011. They had a mean age of 55.4 and most (56%) were male. Patients in the study all had FDG PET-CT scans before beginning their mesothelioma treatment. FDG PET-CT scanning is a powerful imaging tool for mesothelioma and other cancers that combines a radioactive tracer with a combination of positron emission tomography and computed tomography scanning.  Because…

  • | |

    Mesothelioma Surgeons Report New Biopsy Technique

    ByAlex Strauss

    A team of surgeons in Maryland have demonstrated how using a standard biopsy tool in a new way could improve the biopsy process for certain mesothelioma patients. An aggressive cancer of the pleural lining around the lungs, malignant pleural mesothelioma usually requires a tissue biopsy to make a definitive diagnosis. Often this is done using a rigid tool called a thoracoscope inserted into the chest wall while the patient is under general anesthesia. However, mesothelioma doctors at Walter Reed National Military Medical Center detail the case of a 79-year-old suspected mesothelioma patient whose biopsy was done in a minimally-invasive way, under conscious sedation, thanks to the novel use of a standard tool. Although the patient had several of the common signs…

  • |

    New Serum Marker Could Improve Mesothelioma Diagnosis

    ByAlex Strauss

    Japanese researchers believe they have found a way to diagnose a rare form of mesothelioma earlier using a simple blood test. Diffuse malignant peritoneal mesothelioma (DMPM), which represents about a fourth of all mesothelioma cases, is an aggressive malignancy that spreads across the lining of the abdomen. In most cases, DMPM is lethal within a year. The standard treatment for diffuse malignant peritoneal mesothelioma is cytoreductive surgery to remove as much of the mesothelioma as possible, followed by intraperitoneal chemotherapy to destroy residual cancer cells. In some studies, this approach has resulted in 5-year survival rates of 30 to 60 percent. However, it is most successful when it is performed early, while the primary mesothelioma tumor is more easily removed. Like all forms of…